ClinicalTrials.gg
RecruitingNCT07549321SHINEUpdated Nov 20, 2026

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

A Phase 2/3 interventional study of hu1418K322A + Temozolomide + Irinotecan in High-Risk Neuroblastoma, sponsored by Renaissance Pharma Ltd.. Recruiting at 21 sites in 7 countries. Open to participants aged 18 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Renaissance Pharma Ltd. · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 20, 2026First sites in France, Germany and Denmark12 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 469 studies in Neuroblastoma with a site in United States — 54 open to participants now, 103 under way, 4 of them phase 3. Neuroblastoma · United States.

Planned enrollment
43rd of 379
144 · median 31
Started
2026
with 9 others
Phase 2/3
3 of 469
1 open now
Primary completion
2031-03
later than 89 of 100 live
Registered
466th of 469
by date

Among the 469 studies in Neuroblastoma with a site in United States, this one is the 43rd largest by planned enrollment of the 379 interventional ones that give a count, is one of 10 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 89 of the 100 other live ones, and was the 466th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

54 of the 469 studies in Neuroblastoma with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 18 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 469 studies in Neuroblastoma with a site in United States, or all of them as a file.
02

Study summary

Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have high-risk neuroblastoma.

Read the detailed description

This is a Phase 2/3, open label, single arm study, evaluating how well hu14.18K322A works and how safe it is in combination with chemotherapy, in relapsed and refractory high-risk neuroblastoma (HRNB) patients.

The study is in 2 parts. The first part of the study will test two doses of hu14.18K322A to give with chemotherapy in 12 patients to confirm the best dose. Once the best dose is found, Part 2 of the study will recruit up to an additional 66 participants with relapsed disease and 66 participants with refractory disease.

Children and young people who take part in the study must be between 18 months and 18 years old at the time of consent and have confirmed HRNB that has spread to other parts of the body. It is expected that participants will receive up to 12 cycles of treatment. Once the treatment has finished, participants will be followed up to study long-term effects.

03

Conditions studied

  • High-Risk Neuroblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are ≥18 months to \<18 years of age at time of or assent.
  2. Are initially diagnosed with proven HRNB with disease.
  3. Have evaluable or per International Neuroblastoma Response Criteria (INRC)
  4. Have a Lansky performance status of ≥50 (≤16 years ) or performance status ≥50% (for >16 years).
  5. Have recovered from the toxic effects of prior chemotherapies
  6. Are at least 2 weeks beyond any major tumor surgery
  7. Meet the following organ function criteria, as measured within 1 week prior to Medicinal Product (IMP) dosing:

    1. BM function: i. ≥50 × 109/L ii. (ANC) ≥0.50 × 109/L
    2. Renal function: i. Age-adjusted serum creatinine ≤1.5 × (ULN) for age. ii. Estimated (eGFR) at least 60 mL/min using the Schwartz formula.
    3. Liver function: (AST) or alanine aminotransferase (ALT) ≤3 × ULN and total ≤1.5 × ULN.
    4. Cardiac function: i. Shortening fraction ≥27% or of ≥50% on echocardiogram. ii. Interval on (ECG) using the Fridericia formula (QTcF) ≤ 480 msec.
    5. Lung function: i. Pulse oximetry considered normal in room air. No evidence of dyspnea at rest.
    6. Central nervous system (CNS) function: i. Participants with a history of CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment.
  8. If a fertile and sexually active woman of (WOCBP), have a negative serum pregnancy test at Screening and then either a negative serum or urine test prior to each cycle and agree to use an acceptable and highly effective method during the study and for at least 6 months after the last day of study treatment .
  9. If a fertile and sexually active male, agree to use condoms during the study and for at least 6 months after the last dose of study treatment
  10. If applicable based on age, are willing and able to provide voluntary written informed assent for participation in the study (as per local Institutional Review Board [IRB]/Independent Ethics Committee [IEC] requirements and if applicable based on regional age of consent) and to comply with all protocol requirements.
  11. Their parent or legal guardian (if applicable based on regional age of consent) is willing and able to provide voluntary written informed consent for the participant's involvement in the study.

Exclusion criteria

Exclusion Criteria

  1. Any active uncontrolled infection at the time of enrollment. Any known history of infection with (HIV), or active or chronic infection with virus (HBV) or virus (HCV).
  2. Any to any of the study treatments.
  3. Patients with >Grade 2 diarrhea.
  4. Patients with disease of any major organ system that would compromise their ability to withstand chemoimmunotherapy.
  5. Patients who have undergone a prior stem cell transplant \< 6 months ago or have undergone a solid organ transplant.
  6. Patients who are on hemodialysis.
  7. Patients who require or are likely to require pharmacologic doses of systemic while receiving treatment on this study except to manage allergic reactions
  8. Patients on any other medications
  9. Patients who have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, or carbamazepine for at least 7 days prior to study enrollment.
  10. Patients who have been diagnosed with any other than neuroblastoma.
  11. Patients with symptoms of congestive heart failure.
  12. Patients with a history of Grade 4 allergic reactions to anti-GD2 antibodies or reactions that required permanent discontinuation of the anti-GD2 therapy.
  13. Patients participating in or planning to participate in another study that is either blinded or involves an IMP
  14. If female, are breastfeeding, pregnant, or planning to become pregnant, or, if sexually active and of , are unwilling to use an effective method until 6 months after the last dose of study medication
  15. Do not meet the following required prior to the administration of the first dose of hu14.18K322A:

    1. 14 days from prior systemic myelosuppressive chemotherapy.
    2. 7 days from prior systemic biologic antineoplastic agents (e.g. anti-cancer agents not known to be myelosuppressive - not associated with reduced or ANC counts).
    3. 14 days from systemic steroids.
    4. ≥12 weeks from large field radiation therapy (i.e., total body irradiation, whole abdominal, total lung, ≥50% pelvis).
    5. 6 weeks from prior craniospinal radiotherapy or Iodine-131-metaiodobenzylguanidine (131I-MIBG) therapy.
    6. 2 weeks from radiotherapy to the primary tumor bed.
    7. ≥7 days from small treatment field radiation.
    8. 14 days or 5 half-lives (whichever is longer) from last administration of an IMP.
    9. >7 days prior to study enrollment for drugs that are strong inducers or inhibitors of Cytochrome P450 3A4 ().
    10. ≥21 days and with recovery of all associated toxicities from receiving cellular therapy (e.g., modified T lymphocyte cells, Natural Killer (NK) cells, dendritic cells).
  16. Ongoing need for any medication known or suspected to interfere with study treatment.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Other
    Higher dose

    Drug: hu1418K322A + Temozolomide + Irinotecan

  • Other
    Lower dose

    Drug: hu1418K322A + Temozolomide + Irinotecan

Interventions

  • Drughu1418K322A + Temozolomide + Irinotecan

    21-day cycle for a maximum of 12 cycles

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve a complete response (CR) or partial response (PR) according to the International Neuroblastoma Response Criteria (INRC)

    Time frame: Assessed at end of treatment (up to 12 months)

  2. Metastatic complete response rate (mCRR)

    Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve an overall metastatic complete response (mCR) response

    Time frame: Assessed at end of treatment (up to 12 months)

Secondary outcomes

  1. Overall survival (OS)

    Time frame: Up to 3 years

  2. Overall Metastatic Response Rate (mORR)

    Time frame: Assessed at end of treatment (up to 12 months)

  3. Duration of Response (DOR)

    Time frame: From the time of first response until disease progression, discontinuation from study, start of new therapy, or death

  4. Progression-Free Survival (PFS)

    Time frame: From start of Cycle 1 until the first occurrence of progression followed for up to 3 years

  5. Event-Free Survival (EFS)

    Time frame: From start of Cycle 1 until the first occurrence of progression, secondary malignancy, or death due to any cause followed for up to 3 years

07

Study locations

21 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — At the current time there is no plan to share data. We have not received a research proposal that would require utilization of IPD. In the event we receive a request to access IPD a full evaluation will be undertaken and the data will be shared as appropriate and in compliance with the applicable regulations.

No publications or documents are linked to this record.

09

Timeline

9 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2031, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 24, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Mar 2031
CompletionEst.
Mar 2031
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added — first sites in France, Germany and Denmark
Show 12 added (3 France, 3 United States, 2 United Kingdom, 2 Spain, 1 Germany, 1 Denmark)
  • Gustave Roussy · Villejuif, France
  • University of California San Francisco (UCSF) · San Francisco, United States
  • Charité - Universitätsmedizin Berlin · Berlin, Germany
  • Rigshospitalet · Copenhagen, Denmark
  • Royal Marsden NHS Foundation Trust · Sutton, United Kingdom
  • The University of Chicago · Chicago, United States
  • University of Texas Southwestern · Dallas, United States
  • Royal Victoria Infirmary · Newcastle upon Tyne, United Kingdom
  • Hospital Infantil Universitario Niño Jesús · Madrid, Spain
  • Institut Curie · Paris, France
  • La Timone Children's Hospital · Marseille, France
  • Unidad De Oncohematologia Pediatrica · Valencia, Spain
across 9 updates, Sep 28, 2026 – Nov 20, 2026
Show all 9 updates
  1. Nov 20, 2026
    1 site added
    Show site
    • Unidad De Oncohematologia Pediatrica · Valencia, Spain
    + 2 other changes: identifiers and verification date
  2. Nov 3, 2026
    1 site added
    Show site
    • La Timone Children's Hospital · Marseille, France
  3. Oct 30, 2026
    1 site added
    Show site
    • Institut Curie · Paris, France
  4. Oct 26, 2026
    1 site added
    Show site
    • Hospital Infantil Universitario Niño Jesús · Madrid, Spain
  5. Oct 21, 2026
    1 site added
    Show site
    • Royal Victoria Infirmary · Newcastle upon Tyne, United Kingdom
    + 1 other change: verification date
  6. Oct 13, 2026
    2 sites added
    Show 2 added (2 United States)
    • The University of Chicago · Chicago, United States
    • University of Texas Southwestern · Dallas, United States
  7. Oct 8, 2026
    2 sites added — first site in Denmark
    Show 2 added (1 Denmark, 1 United Kingdom)
    • Rigshospitalet · Copenhagen, Denmark
    • Royal Marsden NHS Foundation Trust · Sutton, United Kingdom
  8. Oct 7, 2026
    2 sites added — first site in Germany
    Show 2 added (1 United States, 1 Germany)
    • University of California San Francisco (UCSF) · San Francisco, United States
    • Charité - Universitätsmedizin Berlin · Berlin, Germany
  9. Sep 28, 2026
    1 site added — first site in France
    Show site
    • Gustave Roussy · Villejuif, France

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07549321
Lead sponsor
Renaissance Pharma Ltd.
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Mar 30, 2026
Primary completion
Mar 2031 (estimated)
Completion
Mar 2031 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion